OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
OCUGEN, INC. (OCGN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $10.28 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $10.28M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $18.12M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $7.50M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $12.19M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $10.28M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $18.12M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $7.50M 10-K · filed 2026-03-04 |
| 2025-09-30 | $12.19M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.31M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $575.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $1.13M 10-K · filed 2025-03-05 |
| 2024-09-30 | $1.95M 10-Q · filed 2024-11-14 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-09 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 |
| 2018-06-30 | $867.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $1.21M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $390.00K 10-K · filed 2018-03-15 |
| 2017-09-30 | $327.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $151.00K 10-Q · filed 2017-08-10 |
| 2017-03-31 | $89.00K 10-Q · filed 2017-05-11 |
| 2016-12-31 | $69.00K 10-K · filed 2017-03-16 |
| 2016-09-30 | $253.00K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $56.00K 10-Q · filed 2016-08-11 |
| 2016-03-31 | $95.00K 10-Q · filed 2016-05-12 |
| 2015-12-31 | $4.29M 10-K · filed 2016-03-10 |
| 2015-09-30 | $3.96M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $1.01M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $1.88M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $2.25M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |